An Open Label, Multi-center, IRESSA Clinical Access Prog

Project: Research project

Description

D7913N00017 - An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the continued treatment of patients in the United States who are currently benefiting or have benefited from gefitinib treatment
StatusFinished
Effective start/end date9/1/1112/31/14

Funding

  • United BioSource Corporation

Fingerprint

Therapeutics
gefitinib